Mobile cardiac monitoring is one of the most advanced areas in med tech when it comes to wireless, remote tracking of patients. InfoBionic is hoping to take the technology to the next level by combining three different kinds of cardiac arrhythmia monitoring onto a single system that provides real-time, cloud-based patient data.
Medtronic's fastest growing business is in diabetes, which gained 10% to $430 million in the most recent quarter over a year ago. Now the medical device giant is looking to expand beyond its dominance in Type 1 diabetes that is based on the success of its insulin pump MiniMed. During an earnings call, Medtronic disclosed that it reorganized its diabetes group last quarter.
The only FDA-approved, wearable cancer treatment device may expand its reach. A Phase III trial of Optune (NovoTTF-100A System) from Novocure was halted early due to statistically significant efficacy for the device in combination with chemotherapy to treat newly diagnosed glioblastoma patients.
Dialysis provider DaVita HealthCare Partners has partnered with Medtronic for a pilot program to study cardiac arrhythmias in end-stage renal disease patients receiving dialysis. It will use the tiny implantable cardiac monitor, Linq, which Medtronic launched early this year.
Medtronic's $43 billion acquisition of Covidien has become increasingly expensive, requiring the medical device giant to borrow more than $16 billion, the company said in a massive regulatory filing.
Medtronic submitted concessions to the European Union regulatory commission last Friday. The antitrust authority will decide by Nov. 28 whether to clear the deal.
China's registration review process for imported medical devices and in vitro diagnostics has been shortened under new China FDA importation regulations that took effect last month, and companies that fail to follow the guidelines will not get a second chance, meaning any mistakes could prove fatal to a product's chances in China.
Covidien CEO José Almeida said during the company's fiscal Q4 earnings call that the company's looming megamerger with Medtronic will give the combined entity "a voice at the table" due to its volume in some of the most purchased devices in the world.
Medtronic is celebrating positive study results for its drug-coated balloon device for peripheral artery disease, days after Covidien announced that it would sell off its own drug-coated balloon to clear the way for the companies' pending merger.
Medtronic kicked off the commercialization of its Resolute Onyx drug-eluting stent in Europe today. The device will also be launched in selected countries around the world that recognize the CE mark, but not the U.S., where FDA approval is required.